Margot I. E. Slot

Margot I. E. Slot

Auto-generated profile, based on publicly available information

Margot I. E. Slot

Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2019 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MDMeenakshi Dauwan
Meenakshi Dauwan
MBMarieke J. H. Begemann
Marieke J. H. Begemann
MSMargot I. E. Slot
Margot I. E. Slot
ELEdwin H. M. Lee
Edwin H. M. Lee
PSPhilip Scheltens
Philip Scheltens
ISIris E. C. Sommer
Iris E. C. Sommer
We performed a meta-analysis to synthesize evidence on the efficacy and safety of physical exercise as an add-on therapeutic intervention for quality of life (QoL), depressive symptoms and cognition across six chronic brain disorders: Alzheimer’s disease, Huntington’s disease, multiple sclerosis, Parkinson’s disease, schizophrenia and unipolar depression. 122 studies ( = k) (n = 7231) were included. Exercise was superior to treatment as usual in improving QoL (k = 64,n = 4334, ES = 0.40,p < 0.0001), depressive symptoms (k = 60,n = 2909, ES = 0.78,p < 0.0001), the cognitive domains attention and working memory (k = 21,n = 1313, ES = 0.24,p < 0.009), executive functioning (k = 14,n = 977, ES = 0.15,p = 0.013), memory (k = 12,n = 994, ES = 0.12,p = 0.038) and psychomotor speed (k = 16,n = 896, ES = 0.23,p = 0.003). Meta-regression showed a dose–response effect for exercise time (min/week) on depressive symptoms (β = 0.007,p = 0.012). 69% of the studies that reported on safety, found no complications. Exercise is an efficacious and safe add-on therapeutic intervention showing a medium-sized effect on QoL and a large effect on mood in patients with chronic brain disorders, with a positive dose–response correlation. Exercise also improved several cognitive domains with small but significant effects.

1 November 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
SKSanne Koops
Sanne Koops
JBJan Dirk Blom
Jan Dirk Blom
OBOuarda Bouachmir
Ouarda Bouachmir
MSMargot I. Slot
Margot I. Slot
BNBas Neggers
Bas Neggers
ISIris E. Sommer
Iris E. Sommer

25 October 2024 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
IRInge Winter-Van Rossum
Inge Winter-Van Rossum
MSMargot I E Slot
Margot I E Slot
HHHendrika H van Hell
Hendrika H van Hell
MBMatthijs G Bossong
Matthijs G Bossong
GBGregor Berger
Gregor Berger
RKRene S Kahn
Rene S Kahn
Background and Hypotheses: In the past 2 decades, substantial effort has been put into research on therapeutic options for people at ultra-high risk (UHR) for developing a first episode of psychosis (FEP), focusing on omega-3 polyunsaturated fatty acids (PUFAs) in preventing transition to psychosis. Despite an initial positive finding, subsequent studies failed to find a beneficial effect. The current study aimed to further investigate the effect of omega-3 PUFAs in UHR, to determine whether this line of research is worth pursuing. Study Design: A double-blind, randomized, placebo-controlled study testing the efficacy of 6-month treatment with omega-3 PUFAs in 135 subjects at UHR for FEP, aged 13 to 20 years on the prevention of a transition to psychosis, followed up for 18 months post-treatment. The trial was conducted at 16 general hospitals and psychiatric specialty centers located in 8 European countries and Israel. Study Results: There was no beneficial effect of treatment with omega-3 PUFAs compared to placebo; the rate of transition over 2 years did not differ between treatment arms nor was there a difference in change in symptom severity after 6-month treatment. Dropout rates and serious adverse events were similar across the groups. Conclusions: This is the third study that fails to replicate the original finding on the protective effect of omega-3 PUFAs in UHR subjects for transition to psychosis. The accumulating evidence therefore suggests that omega-3 PUFAs do not reduce transition rates to psychosis in those at increased risk at 2 years follow-up. Clinical Trials: This trial is registered with ClinicalTrials.gov (NCT02597439; Study Details | Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe | ClinicalTrials.gov).

2 March 2024 in Schizophrenia Research
Verified
Journal Article
Open access
MSMargot I.E. Slot
Margot I.E. Slot
HHHendrika H. van Hell
Hendrika H. van Hell
IRInge Winter-Van Rossum
Inge Winter-Van Rossum
PDPaola Dazzan
Paola Dazzan
AMArija Maat
Arija Maat
RKRené S. Kahn
René S. Kahn
We examined the course of illness over a 12-month period in a large, international multi-center cohort of people with a first-episode schizophrenia spectrum disorder (FES) in a naturalistic, prospective study (PSYSCAN). Patients with a first episode of schizophrenia, schizoaffective disorder (depressive type) or schizophreniform disorder were recruited at 16 institutions in Europe, Israel and Australia. Participants (N = 304) received clinical treatment as usual throughout the study. The mean age of the cohort was 24.3 years (SD = 5.6), and 67 % were male. At baseline, participants presented with a range of intensities of psychotic symptoms, 80 % were taking antipsychotic medication, 68 % were receiving psychological treatment, with 46.5 % in symptomatic remission. The mean duration of untreated psychosis was 6.2 months (SD = 17.0). After one year, 67 % were in symptomatic remission and 61 % were in functional remission, but 31 % had been readmitted to hospital at some time after baseline. In the cohort as a whole, depressive symptoms remained stable over the follow-up period. In patients with a current depressive episode at baseline, depressive symptoms slightly improved. Alcohol, tobacco and cannabis were the most commonly used substances, with daily users of cannabis ranging between 9 and 11 % throughout the follow-up period. This study provides valuable insight into the early course of a broad range of clinical and functional aspects of illness in FES patients in routine clinical practice.

7 October 2024 in Schizophrenia
Verified
Journal Article
Open access
PDF file
MSMargot I. E. Slot
Margot I. E. Slot
MCMaria F. Urquijo Castro
Maria F. Urquijo Castro
IRInge Winter - van Rossum
Inge Winter - van Rossum
HHHendrika H. van Hell
Hendrika H. van Hell
DDDominic Dwyer
Dominic Dwyer
RKRené S. Kahn
René S. Kahn
Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize to independent populations. Using a subset of demographic and clinical baseline predictors, we aimed to develop and externally validate different models predicting functional outcome after a FEP in the context of a schizophrenia-spectrum disorder (FES), based on a previously published cross-validation and machine learning pipeline. A crossover validation approach was adopted in two large, international cohorts (EUFEST, n = 338, and the PSYSCAN FES cohort, n = 226). Scores on the Global Assessment of Functioning scale (GAF) at 12 month follow-up were dichotomized to differentiate between poor (GAF current < 65) and good outcome (GAF current ≥ 65). Pooled non-linear support vector machine (SVM) classifiers trained on the separate cohorts identified patients with a poor outcome with cross-validated balanced accuracies (BAC) of 65-66%, but BAC dropped substantially when the models were applied to patients from a different FES cohort (BAC = 50–56%). A leave-site-out analysis on the merged sample yielded better performance (BAC = 72%), highlighting the effect of combining data from different study designs to overcome calibration issues and improve model transportability. In conclusion, our results indicate that validation of prediction models in an independent sample is essential in assessing the true value of the model. Future external validation studies, as well as attempts to harmonize data collection across studies, are recommended.

27 September 2025 in Schizophrenia Research: Cognition
Verified
Journal Article
Open access
MSMargot I.E. Slot
Margot I.E. Slot
HHHendrika H. van Hell
Hendrika H. van Hell
IRInge Winter-Van Rossum
Inge Winter-Van Rossum
GGGeorge Gifford
George Gifford
PDPaola Dazzan
Paola Dazzan
RKRené S. Kahn
René S. Kahn
We examined the course of cognitive performance in first-episode psychosis (FEP) compared to healthy controls (HC), and whether this varied across subgroups of patients defined by premorbid functioning (PMF) trajectories, using a clustering approach. Data were collected in 302 FEP and 136 HC subjects participating in PSYSCAN (HEALTH.2013.2.2.1-2-FEP). K-means clustering (Euclidean distance) was used to cluster longitudinal trajectories of different PMF domains simultaneously. Since PMF was assessed retrospectively using the Premorbid Adjustment Scale (PAS), findings should be interpreted with caution, although PAS ratings have shown reasonable validity against prospective data. As expected, FEP showed impaired performance across all cognitive domains compared to HC. We identified four trajectories of PMF: a normal premorbid developmental trajectory (globally-normal, 21 %), stable intermediate PMF across domains (stable-intermediate, 29 %), stable poor or deteriorating PMF in the academic domain (normal-social/poor-academic, 29 %), and a globally impaired group with poor/deteriorating PMF across domains (globally-poor, 21 %). These clusters showed distinct levels of post-onset impairments in sustained visual attention, visual working memory and emotion recognition. This study confirms a positive association between PMF and cognitive performance in the early years following psychosis onset. It aligns with findings that individuals later diagnosed with schizophrenia already show developmental deficits/lags from childhood to early adolescence compared to normally developing children. As PMF can be considered a proxy for cognitive reserve, our results suggest that higher reserve acts as a buffer against cognitive decline and supports better performance on sustained visual attention, complex visual working memory, and aspects of emotion recognition.